Monitoring teicoplanin levels in children with bacterial infections
Therapeutic Drug Monitoring of Teicoplanin in Children
This study looks at how well teicoplanin works and how much of it kids with bacterial infections need to take to stay safe and healthy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | Shandong University Academic / other |
| Locations | 1 site (Ji'nan, Shandong) |
| Trial ID | NCT03933748 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on monitoring the therapeutic drug levels of teicoplanin in children diagnosed with bacterial infections. It aims to gather data on drug concentration, clinical efficacy, and safety across different age and gender groups. By analyzing the relationship between blood drug concentration and treatment outcomes, the study seeks to provide recommendations for optimal dosing of teicoplanin in pediatric patients in China.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 18 years or younger who are receiving intravenous teicoplanin for therapeutic purposes.
Not a fit: Patients who are receiving teicoplanin for prophylactic purposes or those who do not have therapeutic concentration monitoring will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols for children with bacterial infections, enhancing safety and efficacy.
How similar studies have performed: While there may be limited data on similar studies specifically for teicoplanin in children, therapeutic drug monitoring has shown success in optimizing treatments for various medications in pediatric populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Teicoplanin was administered intravenously; * Teicoplanin was used for therapeutic purposes; * Age:≤18 years; * Clinician confirms and plans to diagnose the patient with gram-positive coccus infection; * Patients with therapeutic concentration monitoring of teicoplanin. Exclusion Criteria: * Teicoplanin was administered non-intravenously; * Teicoplanin was used for prophylactic purposes; * Patients without therapeutic concentration monitoring of teicoplanin; * Patients who die within 24 hours of the use of teicoplanin； * The blood concentrations of the patient was not approved by the quality control center.
Where this trial is running
Ji'nan, Shandong
- Shandong Provincial Qianfoshan Hospital — Ji'nan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Wei Zhao, Ph.D
- Email: zhao4wei2@hotmail.com
- Phone: 86053188383308
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.